Olanzapine, but not haloperidol, enhances PSA-NCAM immunoreactivity in rat prefrontal cortex

16Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Repeated antipsychotic treatment may produce adaptive changes ranging from cytoarchitectural rearrangements to synaptic modifications that might contribute to clinical improvement. We performed a prolonged treatment (2 wk) with the first-generation antipsychotic (FGA) haloperidol (1 mg/kg) and the second-generation antipsychotic (SGA) olanzapine (2 mg/kg twice daily) and analysed the expression of the polysialylated form of neural cell adhesion molecule (PSA-NCAM) in rat hippocampus and prefrontal cortex via immunohistochemistry. We found a regional- and drug-selective increase of PSA-NCAM expression in prefrontal cortex of olanzapine-treated rats with no effects in hippocampus; conversely, haloperidol did not produce a change in either brain region. Our findings reveal a possible role for PSA-NCAM in the mechanism of action of the SGA olanzapine adding complexity as well as specificity to the molecular changes set in motion by this drug. Copyright © 2008 CINP.

Cite

CITATION STYLE

APA

Frasca, A., Fumagalli, F., Ter Horst, J., Racagni, G., Murphy, K. J., & Riva, M. A. (2008). Olanzapine, but not haloperidol, enhances PSA-NCAM immunoreactivity in rat prefrontal cortex. International Journal of Neuropsychopharmacology, 11(5), 591–595. https://doi.org/10.1017/S1461145708009061

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free